Tesi etd-07312018-190750 |
Link copiato negli appunti
Tipo di tesi
Tesi di laurea magistrale LM5
Autore
DI FRANCO, CHIARA
URN
etd-07312018-190750
Titolo
Valutazione di Syndecan-1 e Acido ialuronico come biomarker di alterazione del glicocalice nei pazienti in SIRS
Dipartimento
SCIENZE VETERINARIE
Corso di studi
MEDICINA VETERINARIA
Relatori
relatore Prof.ssa Briganti, Angela
correlatore Dott.ssa Vespi, Gaia Maria
controrelatore Dott.ssa Meucci, Valentina
correlatore Dott.ssa Vespi, Gaia Maria
controrelatore Dott.ssa Meucci, Valentina
Parole chiave
- Cane
- Acido Ialuronico
- Syndecan-1
- SIRS
- Glicocalice
Data inizio appello
14/09/2018
Consultabilità
Non consultabile
Data di rilascio
14/09/2088
Riassunto
Objective- To evaluate the levels of Syndecan-1 and hyaluronic acid in serum and plasma of healthy patients and patients in SIRS, as possible early biomarkers of alteration of the glycocalytic membrane and multi-organ failure.
Material and Methods- 20 healthy dogs from 6 months to 6 years were enrolled for the identification of physiological ranges of syndecan-1 and hyaluronic acid and 25 patients in SIRS (according to the Hauptmann criteria) assigned a SOFA and qSOFA score. Each patient was treated with 5 mL of blood: 2.5 mL for the serum and the same for the plasma; the sample was then centrifuged, separated and frozen at -20 ° C. For the analysis of serum and plasma concentrations of syndecan-1 and of hyaluronic acid, canine monoclonal ELISA kits have been used.
Results- Of the 20 healthy patients, 1 was eliminated due to data inconsistency. Of the 25 ill patients enrolled, 1 patient was eliminated due to lack of data. The total number of patients included was 43, of which 19 were healthy and 24 were ill. The sick patients were divided according to the outcome: 9 survivors and 15 non-survivors.
The dosages of Syndecan-1 in healthy patients were all found to be below the kit determination levels, both for plasma and for serum; on the other hand, for the sick patients, 6 samples out of 15 for serum and 4 samples out of 24 for plasma with values higher in serum than plasma were found above the minimum levels of determination. Statistical analysis did not show any significant difference in syndecan-1 assays among surviving and non-surviving patients even though the latter had higher doses.
With regard to hyaluronic acid, 19 determinations were obtained for both plasma and serum for healthy patients, while for sick patients 15 determinations for serum and 24 for plasma. Statistical analysis showed no significant differences between the values of the healthy and the sick, nor between the surviving and the non-surviving patients.
The analysis of the data did not highlight any significant correlation between the values of syndecan-1 and hyaluronic acid and the scales SOFA / qSOFA.
Conclusions- Plasma determination of syndecan-1 and hyaluronic acid carried out with the kits used in this study does not allow the use of these substances as early biomarkers of glycocalyx alterations.
The use of the SOFA and qSOFA scores, is useful for identifying patients at risk of death.
Material and Methods- 20 healthy dogs from 6 months to 6 years were enrolled for the identification of physiological ranges of syndecan-1 and hyaluronic acid and 25 patients in SIRS (according to the Hauptmann criteria) assigned a SOFA and qSOFA score. Each patient was treated with 5 mL of blood: 2.5 mL for the serum and the same for the plasma; the sample was then centrifuged, separated and frozen at -20 ° C. For the analysis of serum and plasma concentrations of syndecan-1 and of hyaluronic acid, canine monoclonal ELISA kits have been used.
Results- Of the 20 healthy patients, 1 was eliminated due to data inconsistency. Of the 25 ill patients enrolled, 1 patient was eliminated due to lack of data. The total number of patients included was 43, of which 19 were healthy and 24 were ill. The sick patients were divided according to the outcome: 9 survivors and 15 non-survivors.
The dosages of Syndecan-1 in healthy patients were all found to be below the kit determination levels, both for plasma and for serum; on the other hand, for the sick patients, 6 samples out of 15 for serum and 4 samples out of 24 for plasma with values higher in serum than plasma were found above the minimum levels of determination. Statistical analysis did not show any significant difference in syndecan-1 assays among surviving and non-surviving patients even though the latter had higher doses.
With regard to hyaluronic acid, 19 determinations were obtained for both plasma and serum for healthy patients, while for sick patients 15 determinations for serum and 24 for plasma. Statistical analysis showed no significant differences between the values of the healthy and the sick, nor between the surviving and the non-surviving patients.
The analysis of the data did not highlight any significant correlation between the values of syndecan-1 and hyaluronic acid and the scales SOFA / qSOFA.
Conclusions- Plasma determination of syndecan-1 and hyaluronic acid carried out with the kits used in this study does not allow the use of these substances as early biomarkers of glycocalyx alterations.
The use of the SOFA and qSOFA scores, is useful for identifying patients at risk of death.
File
| Nome file | Dimensione |
|---|---|
Tesi non consultabile. |
|